The role of diet and nutritional supplements in preventing and treating cardiovascular disease

Current Opinion in Cardiology

Volumn 24, Issue 5, 2009, Pages 433-441

  Hill, Alison M ^a   Fleming, Jennifer A ^a   Kris Etherton, Penny M ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Dietary approaches to stop hypertension diet; Dietary recommendations; Nutrition supplements; Therapeutic lifestyle changes

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ARGININE; ASCORBIC ACID; BETA CAROTENE; C REACTIVE PROTEIN; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; FISH OIL; FOLIC ACID; GLUTATHIONE PEROXIDASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NICOTINIC ACID; OMEGA 3 FATTY ACID; PYRIDOXINE; REACTIVE OXYGEN METABOLITE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RESVERATROL; SELENIUM; SIMVASTATIN; SODIUM SELENITE; TRIACYLGLYCEROL; UBIDECARENONE; VASCULAR CELL ADHESION MOLECULE 1; VITAMIN B COMPLEX;

ADD ON THERAPY; ALCOHOL ABSTINENCE; ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CALORIC RESTRICTION; CARDIAC PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC PATIENT; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FLUSHING; HEART INFARCTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIVER TOXICITY; MORBIDITY; MORTALITY; NONHUMAN; NUTRITIONAL REQUIREMENT; NUTRITIONAL SUPPORT; OXIDATIVE STRESS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SODIUM RESTRICTION; TREATMENT OUTCOME; VITAMIN SUPPLEMENTATION; WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; DIET; DIET THERAPY; LIFESTYLE; MYOCARDIAL INFARCTION; NUTRITIONAL STATUS; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIET; DIETARY SUPPLEMENTS; FISH OILS; HUMANS; HYPOLIPIDEMIC AGENTS; LIFE STYLE; MYOCARDIAL INFARCTION; NIACIN; NUTRITIONAL STATUS; RISK FACTORS; RISK REDUCTION BEHAVIOR; VITAMIN B COMPLEX;

EID: 69749111974     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e32832f2fb1     Document Type: Review

References (82)

1. U.S. Department of Health and Human Services and U.S. Department of Agriculture. Dietary Guidelines for Americans. 6th ed. Washington, District of Columbia: Government Printing Office; 2005.
2. Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997; 336:1117-1124. (Pubitemid 27374693)
3. Obarzanek E, Sacks FM, Vollmer WM, et al. Effects on blood lipids of a blood pressure-lowering diet: the Dietary Approaches to Stop Hypertension (DASH) Trial. Am J Clin Nutr 2001; 74:80-89. (Pubitemid 32574914)
4. Svetkey LP, Simons-Morton D, Vollmer WM, et al. Effects of dietary patterns on blood pressure: subgroup analysis of the Dietary Approaches to Stop Hypertension (DASH) randomized clinical trial. Arch Intern Med 1999; 159:285-293. (Pubitemid 29075649)
5. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 2001; 344:3-10. (Pubitemid 32064838)
6. Appel LJ, Champagne CM, Harsha DW, et al. Effects of comprehensive lifestyle modification on blood pressure control: main results of the PREMIER clinical trial. JAMA 2003; 289:2083-2093. (Pubitemid 37430210)
7. Elmer PJ, Obarzanek E, Vollmer WM, et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006; 144:485-495. (Pubitemid 46780671)
8. Fung TT, Chiuve SE, McCullough ML, et al. Adherence to a DASH-style diet and risk of coronary heart disease and stroke in women. Arch Intern Med 2008; 168:713-720. (Pubitemid 351563954)
9. Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk. Results from the PREMIER trial. Circulation 2009; 119:2026-2031. This study demonstrates that establish lifestyle recommendations for hypertension, including a DASH diet are effective in reducing CVD risk.
10. Folsom AR, Parker ED, Harnack LJ. Degree of concordance with DASH diet guidelines and incidence of hypertension and fatal cardiovascular disease. Am J Hypertens 2007; 20:225-232.
11. Parikh A, Lipsitz SR, Natarajan S. Association between a DASH-like diet and mortality in adults with hypertension: findings from a population-based follow-up study. Am J Hypertens 2009; 22:409-416.
12. Kotchen TA. Does the DASH diet improve clinical outcomes in hypertensive patients? Am J Hypertens 2009; 22:350.
13. Mellen PB, Gao SK, Vitolins MZ, Goff DC Jr. Deteriorating dietary habits among adults with hypertension: DASH dietary accordance, NHANES 1988-1994 and 1999-2004. Arch Intern Med 2008; 168:308-314.
14. Goodman DS, Hulley SB, Clark, LT, et al. Report of the National Cholesterol Education Program. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch Intern Med 1988; 148:36-69.
15. National Cholesterol Education Program (NCEP) Expert Panel. Summary of the second report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269:3015-3023.
16. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
17. Jenkins DJA, Kendall CWC, Faulkner D, et al. A dietary portfolio approach to cholesterol reduction:combined effects of plant sterols, vegetable proteins, and viscous fibers in hypercholesterolemia. Metabolism 2002; 51:1596-1604. (Pubitemid 36018835)
18. Jenkins DJA, Kendall CWC, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003; 290:502-510. (Pubitemid 37430504)
19. Jenkins DJA, Kendall CWC, Marchie A, et al. Direct comparison of a dietary portfolio of cholesterol-lowering foods with a statin in hypercholesterolemic participants. Am J Clin Nutr 2005; 81:380-387. (Pubitemid 43073339)
20. Jenkins DJA, Kendall CWC, Nguyen TH, et al. Effect of plant sterols in combination with other cholesterol-lowering foods. Metabolism 2008; 57:130-139. This study evaluates the individual cholesterol lowering effectiveness of components of the Portfolio diet.
21. Gigleux I, Jenkins DJ, Kendall CW, et al. Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants. Br J Nutr 2007; 98:1229-1236. (Pubitemid 350193790)
22. St-Pierre AC, Ruel IL, Cantin B, et al. Comparison of various electrophoretic characteristics of LDL particles and their relationship to the risk of ischemic heart disease. Circulation 2001; 104:2295-2299. (Pubitemid 33049511)
23. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-843. (Pubitemid 30165206)
24. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347:1557-1565. (Pubitemid 35315836)
25. Jenkins DJ, Kendall CW, Marchie A, et al. Direct comparison of dietary portfolio vs statin on C-reactive protein. Eur J Clin Nutr 2005; 59:851-860. (Pubitemid 41025263)
26. Lichtenstein AH, Appel LJ, Brands M, et al. Diet and lifestyle recommendations revision 2006: a scientific statement from the American Heart Association Nutrition Committee. Circulation 2006; 114:82-96.
27. Giugliano D, Esposito K. Mediterranean diet and metabolic diseases. Curr Opin Lipidol 2008; 19:63-68.
28. Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr 1995; 61 (6 Suppl):1402S-1406S.
29. Ministry of Health and Welfare. Supreme Scientific Health Council of Greece. Dietary guidelines for adults in Greece. Arch Hellen Med 1999; 16:516-524.
30. Psota TL, Gebauer SK, Kris-Etherton P. Dietary omega-3 fatty acid intake and cardiovascular risk. Am J Cardiol 2006; 98 (4 Suppl 1):3-18. (Pubitemid 44223360)
31. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002; 106:2747-2757. (Pubitemid 35364932)
32. Kris-Etherton PM, Innis S, American Dietetic Association, Dietitians of Canada. Position of the American Dietetic Association and Dietitians of Canada: dietary fatty acids. J Am Diet Assoc 2007; 107:1599-1611.
33. American Diabetes Association. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 2008; 31(Supplement 1):S61-S78.
34. Karpe F, Boquist S, Tang R, et al. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J Lipid Res 2001; 42:17-21. (Pubitemid 32142856)
35. McNamara JR, Shah PK, Nakajima K, et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis 2001; 154:229-236. (Pubitemid 32010711)
36. Kelley DS, Siegel D, Vemuri M, et al. Docosahexaenoic acid supplementation decreases remnant-like particle-cholesterol and increases the (n-3) index in hypertriglyceridemic men. J Nutr 2008; 138:30-35. In this study, DHA supplementation induced favorable changes in RLP-C.
37. Corson MA, Jones PH, Davidson MH. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 2008; 101 (12 Suppl 1):S41-S50.
38. Pedersen MW, Koenig W, Christensen JH, Schmidt EB. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults. Eur J Nutr 2009; 48:1-5.
39. Lanman RB, Wolfert RL, Fleming JK, et al. Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Prev Cardiol 2006; 9:138-143.
40. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015-2022. (Pubitemid 35204692)
41. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99:178-182. (Pubitemid 29035977)
42. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202-1206. (Pubitemid 35398783)
43. Cook JW, Taylor LM, Orloff SL, et al. Homocysteine and arterial disease: experimental mechanisms. Vascul Pharmacol 2002; 38:293-300.
44. Homocysteine Lowering Trialists Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82:806-812.
45. Hodis HN, Mack WJ, Dustin L, et al. High-dose B vitamin supplementation and progression of subclinical atherosclerosis: a randomized controlled trial. Stroke 2009; 40:730-736. This double-blind clinical trial demonstrated a significant reduction in the progression of subclinical atherosclerosis following long-term supplementation with highdose B-vitamins.
46. Mashavi M, Hanah R, Boaz M, et al. Effect of homocysteine-lowering therapy on arterial elasticity and metabolic parameters in metformin-treated diabetic patients. Atherosclerosis 2008; 199:362-367.
47. Nenseter MS, Ueland T, Retterstol K, et al. Dysregulated RANK ligand/RANK axis in hyperhomocysteinemic subjects: effect of treatment with B-vitamins. Stroke 2009; 40:241-247.
48. Ebbing M, Bleie O, Ueland PM, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering b vitamins after coronary angiography: a randomized controlled trial. JAMA 2008; 300:795-804.
49. Albert CM, Cook NR, Gaziano JM, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 2008; 299:2027-2036.
50. Wotherspoon F, Laight DW, Turner C, et al. The effect of oral folic acid upon plasma homocysteine, endothelial function and oxidative stress in patients with type 1 diabetes and microalbuminuria. Int J Clin Pract 2008; 62:569-574. (Pubitemid 351348026)
51. Fernández-Miranda C, Yebra M, Aranda JL, et al. Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease. Int J Cardiol 2007; 118:345-349. (Pubitemid 46678237)
52. Potter K, Hankey GJ, Green DJ, et al. The effect of long-term homocysteine-lowering on carotid intima-media thickness and flow-mediated vasodilation in stroke patients: a randomized controlled trial and meta-analysis. BMC Cardiovasc Disord 2008; 8:24.
53. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15:659-665.
54. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258:94-114.
55. Brown BG, Zhao X-Q, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592. (Pubitemid 33126837)
56. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation 2002; 106:3143-3421.
57. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202:68-75. This study demonstrates a novel anti-inflammatory effect of niacin in endothelial cells.
58. Monget AL, Richard MJ, Cournot MP, et al. Effect of 6 month supplementation with different combinations of an association of antioxidant nutrients on biochemical parameters and markers of the antioxidant defence system in the elderly. The Geriatrie/Min.Vit.Aox Network. Eur J Clin Nutr 1996; 50:443-449.
59. Luoma PV, Sotaniemi EA, Korpela H, Kumpulainen J. Serum selenium, glutathione peroxidase activity and high-density lipoprotein cholesterol: effect of selenium supplementation. Res Commun Chem Pathol Pharmacol 1984; 46:469-472. (Pubitemid 15181834)
60. Salonen JT, Salonen R, Seppanen K, et al. Effects of antioxidant supplementation on platelet function: a randomized pair-matched, placebo-controlled, double-blind trial in men with low antioxidant status. Am J Clin Nutr 1991; 53:1222-1229.
61. Rayman MP. The importance of selenium to human health. Lancet 2000; 356:233-241.
62. Flores-Mateo G, Navas-Acien A, Pastor-Barriuso R, Guallar E. Selenium and coronary heart disease: a meta-analysis. Am J Clin Nutr 2006; 84:762-773. (Pubitemid 44715658)
63. Blankenberg S, Rupprecht HJ, Bickel C, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003; 349:1605-1613. (Pubitemid 37288568)
64. Schnabel R, Lackner KJ, Rupprecht HJ, et al. Glutathione peroxidase-1 and homocysteine for cardiovascular risk prediction: results from the AtheroGene Study. J Am Coll Cardiol 2005; 45:1631-1637. (Pubitemid 40704498)
65. Schnabel R, Lubos E, Messow CM, et al. Selenium supplementation improves antioxidant capacity in vitro and in vivo in patients with coronary artery disease: the SElenium Therapy in Coronary Artery disease Patients (SETCAP) study. Am Heart J 2008; 156:1201.e1-e11. This study reported a substantial increase in the activity of Glutathione Peroxidase following selenium supplementation, which has shown to protect against future CV events.
66. Bjelakovic G, Nikolova D, Gluud LL, et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297:842-857. Data from this meta-analysis showed that vitamin E supplementation may increase all-cause mortality. (Pubitemid 46333949)
67. Bjelakovic G, Nikolova D, Gluud LL, et al. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev 2008:CD007176. (Pubitemid 351807478)
68. Dietrich M, Jacques PF, Pencina MJ, et al. Vitamin E supplement use and the incidence of cardiovascular disease and all-cause mortality in the Framingham Heart Study: does the underlying health status play a role? Atherosclerosis 2008. [Epub ahead of print]
69. Moats C, Rimm EB. Vitamin intake and risk of coronary disease: observation versus intervention. Curr Atheroscler Rep 2007; 9:508-514.
70. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342:154-160. (Pubitemid 30051646)
71. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the women's health study - a randomized controlled trial. JAMA 2005; 294:56-65. (Pubitemid 41002839)
72. Shekelle P, Morton S, Hardy M. Effect of supplemental antioxidants vitamin C, vitamin E, and coenzyme Q10 for the prevention and treatment of cardiovascular disease. Evidence Report/Technology Assessment No. 83. Rockville, Maryland: Agency for Healthcare Research and Quality; 2003.
73. Sander S, Coleman CI, Patel AA, et al. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 2006; 12:464-472. (Pubitemid 46106977)
74. Schaars CF, Stalenhoef AFH. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users. Curr Opin Lipidol 2008; 19:553-557.
75. Gresele P, Pignatelli P, Guglielmini G, et al. Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production. J Nutr 2008; 138:1602-1608.
76. Huynh NN, Chin-Dusting J. Amino acids, arginase and nitric oxide in vascular health. Clin Exp Pharmacol Physiol 2006; 33:1-8.
77. Shakibaei M, Harikumar KB, Aggarwal BB. Resveratrol addiction: to die or not to die. Mol Nutr Food Res 2009; 53:115-128. Extensive review of in vitro, ex vivo and in vivo studies investigating the cardioprotective role of resveratrol.
78. Bai Y, Sun L, Yang T, et al. Increase in fasting vascular endothelial function after short-term oral L-arginine is effective when baseline flow-mediated dilation is low: a meta-analysis of randomized controlled trials. Am J Clin Nutr 2009; 89:77-84. Data from this meta-analysis provide evidence for L-arginine-mediated improvements in vascular function.
79. Ros E, Nunez I, Perez-Heras A, et al. A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover trial. Circulation 2004; 109:1609-1614. (Pubitemid 38451716)
80. Millen AE, Dodd KW, Subar AF. Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: the 1987, and 2000 National Health Interview Survey results. J Am Diet Assoc 2004; 104:942-950.
81. Morris CD, Carson S, U. S. Preventive Services Task Force. Routine vitamin supplementation to prevent cardiovascular disease: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2003; 139:56-70.
82. Kris-Etherton PM, Lichtenstein AH, Howard BV, et al. Antioxidant vitamin supplements and cardiovascular disease. Circulation 2004; 110:637-641. (Pubitemid 39031177)